Abstracts Archive - Page 1394 of 2425 - ACR Meeting Abstracts

Abstract Number: 2827 • 2017 ACR/ARHP Annual Meeting
A Novel Statistical Method to Resolve Cellular Heterogeneity in Disease Tissues: Integrating Transcriptomic Data in Accelerating Medicines Partnership (AMP) – RA Network Phase 1 Data
Fan Zhang¹, Kamil Slowikowski², Chamith Fonseka¹, Kevin Wei³, Maria Gutierrez-Arcelus⁴, James Lederer⁵, Nir Hacohen⁶, Vivian P. Bykerk⁷, Michael Holers⁸, Peter Gregersen⁹, Mandy J. McGeachy¹⁰, Larry W. Moreland¹¹, Andrew Filer¹², Costantino Pitzalis¹³, Yvonne C. Lee¹⁴, Jennifer H. Anolik¹⁵, Michael Brenner⁴ and Soumya Raychaudhuri¹⁶, ¹Divisions of Genetics and Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical Schoo, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Harvard Medical School, Boston, MA, ⁷2-005, Mt Sinai Hospital, Toronto, ON, Canada, ⁸Medicine, Division of Rheumatology, University of Colorado Denver, Aurora, CO, ⁹The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, ¹⁰Medicine, University of Pittsburgh, Pittsburgh, PA, ¹¹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹²Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom, ¹³Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ¹⁴Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁵Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ¹⁶Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Detecting distinct cellular subsets in disease tissues is key to understanding the pathogenesis of immune diseases, for example in synovial tissues in rheumatoid arthritis…
Abstract Number: 2828 • 2017 ACR/ARHP Annual Meeting
A Graph-Theoretic-Approach Applied to Modular-Repertoire-Analysis Identifies Shared Gradual Whole Blood Interferon Signatures in Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome Patients and Reveals New Interferon-Related Modules in Disease Progression
Ilya Korsunski¹, Noémie Jourde-Chiche², Peter Gregersen³, Damien Chaussabel⁴, Laurent Chiche⁵ and Naomi I. Maria⁶, ¹Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ²Nephrology, AP-HM, Department of Nephrology, CHU Conception, Marseille, France, ³Robert S. Boas Center for Genomics and Human Genetics, Feinstein Institute for Med Res, Manhasset, NY, ⁴Translational Medicine, Sidra Medical and Research Center, Doha, Qatar, ⁵Internal medicine, Hopital europeen, Marseille, France, ⁶Center for Autoimmune and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: There is significant clinical and molecular heterogeneity among patients suffering from systemic autoimmune diseases, such as systemic lupus erythematosus (SLE) and primary Sjögren’s Syndrome…
Abstract Number: 2829 • 2017 ACR/ARHP Annual Meeting
Complete Epigenetic Landscape of Rheumatoid Arthritis Fibroblast-like Synoviocytes Reveals Unanticipated Critical Pathogenic Pathways
Rizi Ai¹, Teresina Laragione², Deepa Hammaker³, David L. Boyle⁴, Andre ‎ Wildberg⁵, Keisuke Maeshima³, Emmanuele Palescandolo⁶, Vinod Krishna⁶, Bryan Linggi⁷, David Pocalyko⁸, John W. Whitaker⁹, Percio S. Gulko², Wei Wang¹⁰ and Gary S. Firestein¹¹, ¹UC San Diego, La Jolla, CA, ²Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, ³Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ⁴University of California San Diego, La Jolla, CA, ⁵Chemistry and Biochemistry, UNIVERSITY OF CALIFORNIA SAN DIEGO, LA JOLLA, CA, ⁶Janssen Pharmaceuticals, Spring House, PA, ⁷janssen Pharmaceuticals, Spring House, PA, ⁸Janssen Research, Spring House, PA, ⁹Janssen Pharmaceuticals, La Jolla, CA, ¹⁰Chemistry and Biochemistry, UC San Diego, La Jolla, CA, ¹¹Medicine, University of California San Diego, La Jolla, CA
Background/Purpose: Epigenetics participates in the pathogenesis of rheumatoid arthritis (RA). Epigenetic marks, gene expression and DNA polymorphisms have been investigated but the analyses are limited…
Abstract Number: 2830 • 2017 ACR/ARHP Annual Meeting
Epigenetic Cell Counting: A Novel Tool to Quantify Immune Cells in Salivary Glands Detects Robust Correlations of T Follicular Helper Cells with Immunopathology
Joel A.G. van Roon¹, Frederique M. Moret¹, Sofie L.M. Blokland¹, Aike A. Kruize², Gerben Bouma³, Andre van Maurik³, Sven Olek⁴, Ulrich Hoffmueller⁴ and Timothy R.D.J. Radstake⁵, ¹Rheumatology & Clinical Immunology/ Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Immunoinflammation TAU, GlaxoSmithKline, Stevenage, United Kingdom, ⁴Epiontis GmbH, Berlin, Germany, ⁵Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Histological analysis of salivary glands for decades has been a valuable tool in the characterization of patients with primary Sjögren’s syndrome (pSS) and non-Sjögren’s…
Abstract Number: 2831 • 2017 ACR/ARHP Annual Meeting
Real-World Experience with Tofacitinib Versus Adalimumab and Etanercept in Biologic-Naive Patients with RA Previously Treated with Methotrexate: Data from a US Administrative Healthcare Insurance Claims Database
Tim Smith¹, James Harnett¹, David Gruben², Connie Chen¹, Ekta Agarwal¹ and John Woolcott³, ¹Pfizer Inc, New York, NY, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib access has been restricted by many US payers to use after…
Abstract Number: 2832 • 2017 ACR/ARHP Annual Meeting
Finding the Optimal Treatment Strategy for Disease Activity-Guided Dose Reduction of Adalimumab and Etanercept in Rheumatoid Arthritis: A Modelling Study
D.P.G. Bos¹, L.M. Verhoef¹, C.H.M. van den Ende^1,2, F.H.J. van den Hoogen^1,2, Bruno Fautrel^3,4, M.E.J.L. Hulscher⁵, W. Kievit⁶ and A.A. Den Broeder^1,2, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Radboud university medical centre, Nijmegen, Netherlands, ³UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France, ⁴Paris VI Pierre et Marie Curie University, Paris, France, ⁵Radboud Institute for Health Sciences, IQ healthcare, Radboud university medical centre, Nijmegen, Netherlands, ⁶Department for Health Evidence, Radboud university medical centre, Nijmegen, Netherlands
Background/Purpose: Although bDMARDs are often able to control the RA, they are expensive and associated with adverse effects. Therefore, it is important to use the…
Abstract Number: 2833 • 2017 ACR/ARHP Annual Meeting
Cost-Effectiveness of Competing Anticoagulation Strategies in Knee Replacement Patients
Savannah R. Smith^1,2, Jeffrey N. Katz^3,4 and Elena Losina^3,4, ¹Orthopedics, Brigham and Women's Hospital, Boston, MA, ²George Washington University School of Medicine and Health Sciences, Washington, DC, ³Orthopaedics, Brigham and Women's Hospital, Boston, MA, ⁴Harvard Medical School, Boston, MA
Background/Purpose: Total knee replacement (TKR) patients are routinely prescribed anticoagulation therapy to prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). Clinical guidelines are ambiguous…
Abstract Number: 2834 • 2017 ACR/ARHP Annual Meeting
Healthcare Cost Drivers in Rheumatoid Arthritis
Nina Mars¹, Anne M Kerola^2,3, Markku J Kauppi^4,5, Matti Pirinen¹, Outi Elonheimo⁶ and Tuulikki Sokka-Isler⁷, ¹Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, ²Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ³University of Helsinki, Helsinki, Finland, ⁴School of Medicine, University of Tampere, Tampere, Finland, ⁵Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁶FCG Finnish Consulting Group Ltd., Helsinki, Finland, ⁷Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Rheumatoid arthritis (RA) is associated with high healthcare resource utilization, but knowledge about factors determining healthcare costs is limited. The aim was to identify…
Abstract Number: 2835 • 2017 ACR/ARHP Annual Meeting
5-Year Evolution Patterns of Physical Activity and Sedentary Behavior of Patients with Symptomatic Hip and/or Knee Osteoarthritis, and Their Sociodemographic and Clinical Correlates
Sarah Bitar¹, Abdou Y Omourou^2,3, Aurélie Van-hoye¹, Francis Guillemin^4,5 and Anne-Christine Rat^4,5,6, ¹Université de Lorraine, EA 4360 APEMAC, Nancy, France, ²Université de lorraine, EA 4360 APEMAC, Nancy, France, ³Inserm, CIC-1433 Clinical epidemiology, Nancy, France, ⁴Université de Lorraine, EA4360, APEMAC, Nancy, France, ⁵Inserm, CIC-1433 Epidémiologie Clinique, Vandoeuvre-lès-Nancy, France, ⁶Rheumatology Department, CHRU Nancy, Vandoeuvre-lès-Nancy, France
Background/Purpose: Regular Physical Activity (PA) at a moderate level of intensity for approximately 2.5 hours per week is recommended in the management of hip and/or…
Abstract Number: 2836 • 2017 ACR/ARHP Annual Meeting
The Additional Economic Burden of Depression Among Adults with Rheumatoid Arthritis in the United States
Nan Li and Steven Peterson, Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Depression is significantly more prevalent in patients with rheumatoid arthritis (RA) compared with the general population.1 It has a significant effect on RA patients,…
Abstract Number: 2837 • 2017 ACR/ARHP Annual Meeting
Cross-Sectional Analysis of Chikungunya Arthritis Patients 22-Months Post-Infection Demonstrates a Lack of Viral Persistence in Synovial Fluid
Aileen Chang¹, Karen Martins* Contributed equally², Liliana Encinales³, St. Patrick Reid⁴, Marlon Acuña³, Carlos Encinales³, Christian Matranga⁵, Nelly Pacheco³, Carlos Cure³, Bhavarth Shukla⁶, Teofilo Arteta Ruiz³, Richard Amdur⁷, Lisa Cazares⁸, Melissa Gregory⁸, Michael Ward⁸, Alexandra Porras⁹, Alejandro Rico Mendoza⁹, Lian Dong⁸, Tara Kenny⁸, Ernie Brueggemann⁸, Lydia Downey⁸, Priyanka Kamalapathy⁷, Paola Lichtenberger⁶, Orlando Falls³, Gary Simon⁷, Jeffrey Bethony⁷ and Gary S. Firestein¹⁰, ¹Medicine, George Washington University, Washington, DC, ²United States Army Medical Research Institute for Infectious Disease, Frederick, MD, ³Allied Research Society, Baranquilla, Colombia, ⁴University of Nebraska, Omaha, NE, ⁵Broad Institute, Boston, MA, ⁶University of Miami, Miami, FL, ⁷George Washington University, Washington, DC, ⁸United States Army Medical Research Institute of Infectious Disease, Frederick, MD, ⁹Allied Research Society, Bogota, Colombia, ¹⁰Medicine, UCSD, La Jolla, CA
Background/Purpose: Chikungunya virus infection is a mosquito-borne disease that causes chronic joint pain for months to years in approximately one half of infected patients. The…
Abstract Number: 2838 • 2017 ACR/ARHP Annual Meeting
Apoptotic Bodies Containing dsDNA Covalently Modified By Parvovirus B19 Non-Structural Protein NS1 Induce dsDNA Autoantibodies and End Organ Damage in Non-Autoimmune Mice
Stanley J. Naides¹, Kanoktip Puttaraksa², Heidi Pirttinen² and Leona Gilbert², ¹Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ²Department of Biological and Environmental Science and Nanoscience Center, University of Jyvaskyla, Jyvaskyla, Finland
Background/Purpose: Persistent viral infections can induce aberrant immune responses and are implicated in the development of autoimmunity. Parvovirus B19 (B19V) non-structural protein, NS1, a helicase,…
Abstract Number: 2839 • 2017 ACR/ARHP Annual Meeting
Practice Patterns of Pneumocystis Pneumonia Prophylaxis in Connective Tissue Diseases: a Survey of Infectious Disease Physicians
Rachel M. Wolfe¹, Susan E. Beekmann², Philip M. Polgreen² and James E. Peacock Jr.³, ¹Internal Medicine, Section on Rheumatology and Immunology, Wake Forest Baptist Health, Winston-Salem, NC, ²Internal Medicine, Division of Infectious Diseases, Carver College of Medicine, Iowa City, IA, ³Internal Medicine, Section on Infectious Disease, Wake Forest Baptist Health, Winston-Salem, NC
Background/Purpose: Potent immunosuppressive therapy for connective tissue diseases (CTDs) imparts an increased risk for opportunistic infections including Pneumocystis pneumonia (PCP). High mortality rates have been…
Abstract Number: 2840 • 2017 ACR/ARHP Annual Meeting
Clinical Presentation and Outcomes in Patients with Prosthetic Joint Septic Arthritis Who Had One-Stage Versus Two-Stage Joint Replacement
Mary Louise Fowler¹, Kevin Byrne², Sarah Lieber³, Robert Shmerling⁴ and Ziv Paz³, ¹2Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Beth Israel Deaconess Medical Center, Boston, MA, ⁴Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Prosthetic joint septic arthritis (PJSA) complicates about 1 to 2 percent of joint replacement surgeries. The management of PJSA usually includes a combination of…
Abstract Number: 2841 • 2017 ACR/ARHP Annual Meeting
Infection Is the Major Trigger of Adult Hemophagocytic Syndrome, an Orphan Systemic Hyperinflammatory, Life-Threatening Disease: Analysis in 147 Patients (GEAS-SEMI Registry)
Pilar Brito-Zerón¹, Alejandra Flores-Chavez^2,3,4, Pedro Moral Moral⁵, A. Martínez-Zapico⁶, Pilar Hernández-Jimenez⁷, Guadalupe Fraile Rodriguez⁸, Patricia Perez Guerrero⁹, Eva Fonseca¹⁰, Angel Robles¹¹, María Vaquero Herrero¹², Angela Ruiz de Temiño de la Peña¹³, Maria José Forner¹⁴, José Ramón Larrañaga¹⁵, Mónica Rodriguez Carballeira¹⁶, Luis Fernando Viejo Llorente¹⁷, Manuel Ruiz Muñoz¹⁸, Roberto Hurtado¹⁹, César Morcillo²⁰, Soledad Retamozo²¹ and Manuel Ramos-Casals^22,23, ¹Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, ²Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona, Spain., Barcelona, Spain, ³Programa de Doctorado en Ciencias Médicas, Centro Universitario de Investigaciones Biomédicas (CUIB), Universidad de Colima, Colima, Mexico, Mexico, Mexico, ⁴Unidad de Investigación Biomédica 02 (Unidad de Investigación en Epidemiología Clínica), UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Jalisco, Mexico, ⁵Hospital La Fé Valencia, Valencia, Spain, ⁶Hospital Universitario de Asturias, Oviedo, Oviedo, Spain, ⁷Internal Medicine, Hospital 12 de Octubre, Madrid, Spain, ⁸Internal Medicine, Hospital Ramón y Cajal, Madrid, Madrid, Spain, ⁹Department of Internal Medicine, Hospital Universitario Puerta del Mar, Cádiz, Cadiz, Spain, ¹⁰Internal Medicine, Hospital de Cabueñes, Gijón, Gijón, Spain, ¹¹Internal Medicine, Hospital La Paz, Madrid, Madrid, Spain, ¹²Complejo Asistencial Universitario de Salamanca, Salamanca, Spain, ¹³Hospital Rio Hortega Valladolid, Valladolid, Spain, ¹⁴Department of Internal Medicine, Hospital Clínico de Valencia, Valencia, Spain, ¹⁵Department of Internal Medicine, Hospital Xeral, Vigo, Vigo, Spain, ¹⁶Hospital Mutua de Terrasa, Terrasa, Spain, ¹⁷Hospital Virgen de la Salud Toledo, Toledo, Spain, ¹⁸Department of Internal Medicine, Hospital Universitario Fundacion Alcorcón, Madrid, Spain, ¹⁹Hospital Vega Baja de Orihuela, Alicante, Spain, ²⁰Department of Medicine, Hospital CIMA-Sanitas, Barcelona, Barcelona, Spain, ²¹Rheumatology Unit, Hospital Privado Universitario de Córdoba, Institute University of Biomedical Sciences University of Córdoba (IUCBC), Cordoba, Argentina, ²²Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ²³Department of Medicine, University of Barcelona, Barcelona, Spain., Barcelona, Spain
Background/Purpose: Hemophagocytic syndrome or hemophagocytic lymphohistiocytosis (HLH) is an increasingly-recognized condition in adults, characterized by a wide range of etiologies, symptoms and outcomes, but with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].